MBX Biosciences Inc (MBX)
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders. Its lead candidate, Canvuparatide (MBX 2109), is a parathyroid hormone peptide prodrug being evaluated in Phase 3 for chronic hypoparathyroidism. The company is also advancing Imapextide (MBX 1416), a long-acting GLP-1 receptor antagonist in Phase 2 for post-bariatric hypoglycemia, a complication that can follow bariatric surgery. In addition, MBX Biosciences is developing MBX 4291, an obesity-focused candidate in investigational new drug-enabling studies for obesity and related comorbidities. Founded in 2018, the company is based in Carmel, Indiana.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-MBX
|
$62.19
|
5.3% Upside
|
Fair
|
$69
|
16.8% Upside
|
Fair
|
Good
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-32.5x
|
6.4x
|
—
|
2.863 B
|
2.373 B
|
0.0%
|
56.8%
|
114.6
|
—
|
92.2%
|
